

- IV. Claims 1-31, drawn to the compounds and compositions of the formula depicted in claim 1 wherein X is N, n=4, classified in class 546, subclass 184.
- V. Claims 1-31, drawn to the compounds and compositions of the formula depicted in claim 1 wherein X is N, n=5, classified in class 540, subclass 596.
- VI. Claims 1-31, drawn to the compounds of the formula depicted in claim 1 wherein X is CR5, n=1, classified in class 544, subclass 242.
- VII. Claims 1-31, drawn to the compounds and composition not included in Groups I-VI, classified in classes and subclasses depending on the nature of the substituents.

VIII-XV. Claims 32-43, drawn to one of the methods for treatment of seven disorders, classified in class 514 and various subclasses.

XVI. Claims 44-62, drawn to a combination of a compound as defined in 1 and another pharmaceutical agent, classified in classes and subclasses depending on the nature of the other pharmaceutical agent."

Applicants elect for purposes of prosecution Group IV Claims 1 to 31, that is compounds of Claim 1 wherein X is N and n=4.

Claims readable on the Group IV invention include Claims 1 to 3, 6 to 10, 12 to 20, 22 in part, 24 in part, 25 in part, 26, 27 in part, 28 in part, 29 in part, 30 and 31 to 62.

Should Applicants be required to select a single disclosed species, Applicants select the species of Example 313.

It is believed that this application is in good form for full examination.

Respectfully submitted,



Burton Rodney
Attorney for Applicants
Reg. No. 22,076

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4336

Date: Aug. 16, 2061